Price
CHART BY
Frequently asked questions
What is GeneDx Holdings's market capitalization?
The market capitalization of GeneDx Holdings is $2.38B. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.
What is the Earnings Per Share (EPS) for GeneDx Holdings?
GeneDx Holdings's Earnings Per Share (EPS) over the trailing twelve months (TTM) is -$3.629. EPS indicates the company's profitability on a per-share basis.
What are the analyst ratings and target price for GeneDx Holdings's stock?
Currently, 9 analysts cover GeneDx Holdings's stock, with a consensus target price of $90.44. Analyst ratings provide insights into the stock's expected performance.
What is GeneDx Holdings's revenue over the trailing twelve months?
Over the trailing twelve months, GeneDx Holdings reported a revenue of $454.43M.
What is the EBITDA for GeneDx Holdings?
GeneDx Holdings's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is -$29.87M. EBITDA measures the company's overall financial performance.
What is the free cash flow of GeneDx Holdings?
GeneDx Holdings has a free cash flow of -$75.80M. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.
How many employees does GeneDx Holdings have, and what sector and industry does it belong to?
GeneDx Holdings employs approximately 1,300 people. It operates in the Health Care sector, specifically within the Medical/ Nursing Services industry.
What is the free float of GeneDx Holdings's shares?
The free float of GeneDx Holdings is 27.53M. Free float refers to the number of shares available for public trading, excluding restricted shares.
Financials
- Market Cap
- $2.38B
- EPS (TTM)
- -$3.629
- Free Float
- 27.53M
- Revenue (TTM)
- $454.43M
- EBITDA (TTM)
- -$29.87M
- Free Cashflow (TTM)
- -$75.80M
Pricing
- 52W span
- $32.22$170.31
Analyst Ratings
The price target is $90.44 and the stock is covered by 9 analysts.
Buy
9
Hold
0
Sell
0
Information
GeneDx Holdings Corp. is a rare disease diagnosis company, with a mission to empower everyone to live their healthiest life through genomics. The firm combines clinical expertise, advanced technology, and the power of GeneDx Infinity. This foundation powers GeneDx's ExomeDx and GenomeDx tests, enabling clinicians to deliver precise, fast, and actionable diagnoses. The Infinity also fuels discovery for biopharma with AI-driven genomic intelligence. The company was founded by Eric Schadt in October 2015 and is headquartered in Stamford, CT.
- Employees
- 1,300
- Industries
- Medical/ Nursing Services
- Sector
- Health Care
Identifier
- Primary Ticker
- WGS
Fundamentals & EOD data from FactSet